For example, a negative effect of FCGR2A rs1801274 was detected for the development of pneumonia in systemic lupus erythematosus patients [15]; additionally, FCGR2A rs1801274 was not found to increase the risk of invasive pneumococcal disease in Belgium [16]. Here, FCGR2A is linked to systemic lupus erythematosus.